BCAX · Bicara Therapeutics

The thesis

Bicara Therapeutics' shares are more likely to lag the S&P 500 over the next three months. Genmab's rival head-and-neck cancer drug has won a Phase 3 trial, and Bicara's own randomized data for ficerafusp alfa do not arrive until mid-2027. The third-quarter report on 9 November 2026 removed a timing and funding worry. It did not change the competitive picture.

Bicara said on 9 November 2026 that its pivotal FORTIFI-HN01 trial in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC) has reached substantial enrollment, with topline interim results expected in mid-2027 (company 8-K). Cash, cash equivalents and marketable securities were $442.3 million at 30 September 2026, and the company still guides runway into the first half of 2029.

The shares closed at $10.53 on 11 November 2026, down 55.4% over three months and 66.0% below the 52-week intraday high of $30.99 set on 7 July 2026. The price reflects a much smaller first-line market for ficerafusp alfa than before Genmab's 28 October 2026 result: Investing.com put Bicara's market value at $646 million when the shares traded at $9.73 on 29 October 2026, little more than the cash balance.

The rating is Low because the next three months hold no randomized data for ficerafusp alfa. The events in that window are investor conferences, preclinical data and an early colorectal cancer readout in January 2027. Genmab's full LiGeR-HN1 presentation, with no date set, is more likely to move the shares than any Bicara event.

Bullish and bearish views on Bicara Therapeutics Inc.

The bull case on Bicara Therapeutics Inc. (BCAX), in brief: the pivotal trial is fully on track. The bear case: a rival has randomized survival data.

Bull case

• The pivotal trial is fully on track. Bicara reported substantial enrollment in FORTIFI-HN01 on 9 November 2026, ahead of its year-end 2026 target, which keeps the mid-2027 interim analysis on schedule (company 8-K).
• Cash covers most of the market value. Cash and marketable securities were $442.3 million at 30 September 2026, up from $414.8 million at 31 December 2025, with runway into the first half of 2029 (Q3 2026 8-K).
• Brokers kept Buy ratings after the report. Stifel cut its target to $43 and BTIG to $37 on 10 November 2026. Morgan Stanley cut its target to $30 the same day and kept an Overweight rating. HC Wainwright cut its target to $36 on 11 November 2026 and kept a Buy rating (company news).
• The rival trial targets a different population. LiGeR-HN1 enrolled PD-L1-positive patients and compared petosemtamab plus pembrolizumab with pembrolizumab alone (Clinical Trials Arena, 28 October 2026). FORTIFI-HN01 targets HPV-negative patients, so the two trials do not test the drugs head to head.
• A second indication is coming. Bicara plans to present Phase 1b expansion data in third-line-or-later metastatic colorectal cancer in January 2027 (Q3 2026 8-K).

Bear case

• A rival has randomized survival data. Genmab reported on 28 October 2026 that petosemtamab plus pembrolizumab cut the risk of death by 50% in LiGeR-HN1 (Clinical Trials Arena). Bicara's survival figures come from single-arm cohorts with no control group.
• Earlier-stage numbers favour the rival. Genmab reported a Phase 2 median overall survival of 28.2 months for petosemtamab in 43 evaluable patients in late October 2026. Investing.com reported 21.3 months for ficerafusp alfa in HPV-negative patients. The trials enrolled different patients.
• Losses roughly doubled in a year. Third-quarter 2026 research and development expense was $56.5 million against $33.0 million a year earlier. General and administrative expense was $19.2 million against $7.7 million, and the net loss was $71.2 million against $36.3 million (Q3 2026 8-K).
• A major broker turned negative. Goldman Sachs downgraded the shares to Sell on 29 October 2026. It called the first-line market winner-take-most (Investing.com).
• Leadership is interim. Ryan Cohlhepp is serving as interim chief executive. The 9 November 2026 release does not mention a search for a permanent CEO.

Price setup

The 52-week closing low is $7.93, set on 2 November 2026 after the Genmab news. The shares closed at $8.19 on 5 November 2026 and $8.65 on 6 November 2026. They then closed at $9.98 on 9 November 2026, the day of the third-quarter report, and at $10.53 on 11 November 2026.

The rebound has not reached the averages. The 50-day moving average was $17.37 and the 200-day moving average $20.90 as of 11 November 2026, both far above the last close. The close three months earlier was $23.63 on 13 August 2026. The October collapse left a wide gap between the current price and every level the shares held before 28 October 2026.

The report-day move shows how much of the recovery rests on the funding and enrollment update. Broker targets reset after the report ranged from $30 to $43 (company news, 10 November 2026 and 11 November 2026). Those targets are still well above the 52-week high's distance from the current price.

Catalysts ahead

• 16 November 2026: Bicara presents at the Jefferies investor conference. This is the first management appearance after the Q3 report. It may show how management positions ficerafusp alfa against petosemtamab in HPV-negative patients.
• 2 December 2026: Bicara presents at the Piper Sandler healthcare conference. This is a further update on FORTIFI-HN01 follow-up and commercial preparation before the mid-2027 interim analysis.
• ~14 December 2026 (est.): Preclinical data on tumor-targeted TGF-beta neutralization at the ESMO IO & Advanced Therapies Congress (14 December to 16 December 2026). The data support the mechanism behind ficerafusp alfa. Preclinical results are unlikely to change the competitive case alone.
• ~15 January 2027 (est.): Phase 1b expansion data in third-line-or-later metastatic colorectal cancer (company guides January 2027). Strong responses would give ficerafusp alfa a second indication outside the contested head-and-neck market.
• ~30 June 2027 (est.): FORTIFI-HN01 topline interim analysis (company guides mid-2027). This is the first randomized test of ficerafusp alfa. It decides the clinical case and whether the drug can compete with petosemtamab.

What would change the view

A daily close above $12.32, which would carry the post-results rebound well beyond the early-November closes and show the shares leading the S&P 500; so would a partnering deal or takeover offer for Bicara.

What it trades with

Bicara trades on the competitive picture in first-line head-and-neck cancer. The reference programs are Genmab's petosemtamab and Johnson & Johnson's amivantamab. Bicara fell sharply in the sessions after Genmab's 28 October 2026 announcement, and Genmab's full LiGeR-HN1 data will hit Bicara directly.

The shares also move with small-cap clinical-stage biotech, which depends on funding conditions and the wider biotech index. The latest itemised insider trade is a SEC Form 4 filed 10 September 2026. It shows President, chief operating officer and interim CEO Ryan Cohlhepp exercising options on 17,500 shares at $3.79 on 8 September 2026 and selling 17,500 shares at an average of $22.90 the same day, under a Rule 10b5-1 trading plan.